Caffeine and its byproducts (metabolites) after intake in the human body.
â€œearly diagnostic biomarkers for the [Parkinsonâ€™s] diseaseâ€�; moreover, the results â€œfurther indicated the neuroprotective effects of caffeineâ€�
TOKYO (PRWEB UK) 15 February 2018
February 15, 2018
Source: Juntendo University Corporate Communications
(Tokyo, 15 February) Researchers at Juntendo University report in Neurology the potential use of blood levels of caffeine and its byproducts as biomarkers for Parkinsonâ€™s disease. The finding is promising for the development of a method enabling early identification of the disease.
Parkinsonâ€™s disease is a degenerative disorder of the central nervous system, affecting the latterâ€™s motor system â€” the part controlling bodily motion. Its symptoms include shaking, rigidity and difficulty with walking. There is evidence that daily caffeine consumption reduces the risk of developing Parkinsonâ€™s. Now, a team of researchers led by Nobutaka Hattori from Juntendo University School of Medicine have studied how traces of caffeine in the blood, after drinking coffee, can be indicative of Parkinsonâ€™s disease. The researchers found that caffeine levels are significantly lower in patients with the disease; caffeine concentrations could therefore be used as an indicator of Parkinsonâ€™s, particularly in its early stages.
The researchers studied a group of 139 people, both men and women, with and without Parkinsonâ€™s disease. Each person drank between 0 and 5 cups of coffee per day (except for one participant who drank more than six). Then, they checked the participantsâ€™ blood serum for traces of caffeine and its 11 so-called downstream metabolites â€” small molecules produced during caffeine-induced metabolic processes in the human body.
Video: Professor Nobutaka Hattori describing his group's research on Parkinson's disease.
Video: Professor Shinji Saiki describing the details of the research published in Neurology, January 3, 2018.
The scientists found that the serum levels of caffeine and of almost all metabolites, including theophylline, theobromine and paraxanthine â€” caffeineâ€™s main byproducts â€” were lower in patients with Parkinsonâ€™s disease. Although the data obtained by Hattoriâ€™s team show that there is a clear relation between a personâ€™s caffeine (metabolite) serum levels and having Parkinsonâ€™s disease, there was no significant association between the severity of the disease and the concentration of any of the caffeine-related substances. Also, there was no significant difference in serum levels between male and female patients (males are known to suffer more often from Parkinsonâ€™s disease).
The findings of Hattori and colleagues suggest that caffeine and caffeine metabolite levels in the blood can be, quoting the researchers, â€œearly diagnostic biomarkers for the [Parkinsonâ€™s] diseaseâ€�; moreover, the results â€œfurther indicated the neuroprotective effects of caffeineâ€�.
In patients suffering from Parkinsonâ€™s disease, progressive loss of the function or structure of neurons (brain cells) leads to a disorder of the central nervous system, affecting its motor system. Tremor, slowness of movement and difficulties with walking are among the main symptoms in the early stages of Parkinsonâ€™s, with dementia being common at more advanced stages.
The cause of Parkinsonâ€™s disease is unclear, but it is believed that genetic and environmental factors play a role. Men are more affected than women, and people who drink tea or coffee have a reduced risk. The latter inspired Nobutaka Hattori and colleagues from Juntendo University School of Medicine to check whether caffeine levels in the blood, and levels of the byproducts (metabolites) that caffeine intake causes, can be used as biomarkers for the diagnosis of Parkinsonâ€™s disease. They found that this is indeed the case.
Caffeine is an organic molecule that, when consumed through e.g. coffee or tea, stimulates the central nervous system. Its best-known effect is the prevention of (the onset of) drowsiness. Daily caffeine consumption has been shown to reduce the risk of developing Parkinsonâ€™s disease in men, and in women not taking hormone replacement therapy â€” caffeineâ€™s neuroprotective effect.
The team of Nobutaka Hattori has now demonstrated that, following caffeine intake, the levels of caffeine and its metabolites in the blood serum are lower for people with Parkinsonâ€™s, independent of the stage of the disease, implying that these levels could be used as biomarkers for the disease in the early stage.
Motoki Fujimaki, Shinji Saiki, Yuanzhe Li, Naoko Kaga, Hikari Taka, Taku Hatano, Kei-Ichi Ishikawa, Yutaka Oji, Akio Mori, Ayami Okuzumi, Takahiro Koinuma, Shin-Ichi Ueno, Yoko Imamichi, Takashi Ueno, Yoshiki Miura, Manabu Funayama & Nobutaka Hattori. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology, January 3, 2018.
Home page: http://www.juntendo.ac.jp/english/
Juntendo was originally founded in 1838 as a Dutch School of Medicine at a time when Western medical education was not yet embedded as a normal part of Japanese society. With the creation of Juntendo, the founders hoped to create a place where people could come together with the shared goal of helping society through the powers of medical education and practices. Their aspirations led to the establishment of Juntendo Hospital, the first private hospital in Japan. Through the years the institutionâ€™s experience and perspective as an institution of higher education and a place of clinical practice has enabled Juntendo University to play an integral role in the shaping of Japanese medical education and practices. Along the way the focus of the institution has also expanded, now consisting of four undergraduate programs and three graduate programs, the university specializes in the fields of health and sports science and nursing health care and sciences, as well as medicine. Today, Juntendo University continues to pursue innovative approaches to international level education and research with the goal of applying the results to society.
Latest posts by Jasmine Petters (see all)
- ICC-SRCC and APSP Release New Solar Pool and Spa Heating System Standard - February 22, 2018
- FDAnews Announces â€” New Direct Marking Requirements for UDIs: How to Comply with the Final Guidance Webinar, March 6, 2018 - February 22, 2018
- Digital Signature Market Projected to Boost the Growth of Market in Near Future: By Types on-Premise, Cloud - February 22, 2018